Cargando…

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

SIMPLE SUMMARY: The combination of everolimus and exemestane was FDA approved after BOLERO-2 clinical trial results for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC), progressing on a prior therapy with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirico, Marianna, Bernocchi, Ottavia, Sobhani, Navid, Giudici, Fabiola, Corona, Silvia P., Vernieri, Claudio, Nichetti, Federico, Cappelletti, Maria Rosa, Milani, Manuela, Strina, Carla, Cervoni, Valeria, Barbieri, Giuseppina, Ziglioli, Nicoletta, Dester, Martina, Bianchi, Giulia Valeria, De Braud, Filippo, Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697290/
https://www.ncbi.nlm.nih.gov/pubmed/33182575
http://dx.doi.org/10.3390/cancers12113314
_version_ 1783615578754252800
author Sirico, Marianna
Bernocchi, Ottavia
Sobhani, Navid
Giudici, Fabiola
Corona, Silvia P.
Vernieri, Claudio
Nichetti, Federico
Cappelletti, Maria Rosa
Milani, Manuela
Strina, Carla
Cervoni, Valeria
Barbieri, Giuseppina
Ziglioli, Nicoletta
Dester, Martina
Bianchi, Giulia Valeria
De Braud, Filippo
Generali, Daniele
author_facet Sirico, Marianna
Bernocchi, Ottavia
Sobhani, Navid
Giudici, Fabiola
Corona, Silvia P.
Vernieri, Claudio
Nichetti, Federico
Cappelletti, Maria Rosa
Milani, Manuela
Strina, Carla
Cervoni, Valeria
Barbieri, Giuseppina
Ziglioli, Nicoletta
Dester, Martina
Bianchi, Giulia Valeria
De Braud, Filippo
Generali, Daniele
author_sort Sirico, Marianna
collection PubMed
description SIMPLE SUMMARY: The combination of everolimus and exemestane was FDA approved after BOLERO-2 clinical trial results for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC), progressing on a prior therapy with a non-steroideal aromatase inhibitor. However, there are no predictive biomarkers for tumor sensitivity or resistance to everolimus-based treatment. The aim of our retrospective study was to investigate the potential role of FDG-PET SUV (ΔSUV%) as a predictive biomarker for a long-term clinical benefit. We found in a homogenous population of 31 patients two precocious ∆SUV% thresholds capable of identifying HR+ HER2-mBC patients achieving long-term benefit or long-term survival (36 month-OS) during everolimus-exemestane therapy. Based on these results, ∆SUV, as PET-based biomarker, provides additional information on which patients are most likely to benefit from everolimus with exemestane-based therapy over a long-term period. FDG-PET is a useful and minimally invasive tool that could be used for making a decision on personal treatment enhancing benefit while reducing collateral effects. ABSTRACT: Background: The mTORC1 inhibitor everolimus has been approved in combination with the aromatase inhibitor exemestane for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC) progressing on prior therapy with a non-steroidal aromatase inhibitor. To date, no predictive biomarkers of tumor sensitivity/resistance for everolimus-based treatments have been identified. We hypothesized that precocious changes in the Standardized Uptake Volume (∆SUV%), as assessed by (18)F-Fluorodeoxyglucosepositron-emission tomography ((18)F-FDG PET/CT), may be a marker of everolimus efficacy. Methods: This was a retrospective study including 31 HR+ HER2- patients treated with everolimus and exemestane in two Italian centers between 2013 and 2018. The objective of the study was to investigate ∆SUV% as a predictive marker of everolimus antitumor efficacy. (18)F-FDG PET/CT scans were performed at baseline and after three months of treatment. Patients were defined as long responders (LRs) if disease progression occurred at least 10 months after treatment initiation and long survivors (LSs) if death occurred later than 36 months after starting therapy. ROC analysis was used to determine the optimal cut-off values of ∆SUV% to distinguish LRs from non-LRs and LSs from non-LSs. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan–Meier method. Results: The SUVmax values decreased significantly from baseline to 3 months after therapy (p = 0.003). Dynamic changes of SUVmax (Delta SUV) had a higher accuracy in discriminating long-responders from non-long-responders (AUC = 0.67, Delta SUV cut-off = 28.8%) respects to its ability to identify long survivors from no-long survivors (AUC = 0.60, Delta SUV cut-off = 53.8%). Patients were divided into groups according to the Delta SUV cut-offs and survival outcomes were evaluated: patients with a decrease of ∆SUV% ≥ 28.8% had significantly better PFS (10 months-PFS: 63.2%, 95% CI: 37.9–80.4% and 16.7%, 95% CI: 2.7–41.3% respectively, p = 0.005). As regard as OS, patients with ∆SUV% ≥ 53.8% had longer OS when compared to patients with ∆SUV% < 53.8% (36 month-OS: 82.5% vs. 45.9% vs. p = 0.048). Conclusion: We found two precocious ∆SUV% thresholds capable of identifying HR+ HER2-mBC patients, which would achieve long-term benefit or long-term survival during everolimus-exemestane therapy. These results warrant further validation in prospective studies and should be integrated with molecular biomarkers related to tumor metabolism and mTORC1 signaling.
format Online
Article
Text
id pubmed-7697290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76972902020-11-29 Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Sirico, Marianna Bernocchi, Ottavia Sobhani, Navid Giudici, Fabiola Corona, Silvia P. Vernieri, Claudio Nichetti, Federico Cappelletti, Maria Rosa Milani, Manuela Strina, Carla Cervoni, Valeria Barbieri, Giuseppina Ziglioli, Nicoletta Dester, Martina Bianchi, Giulia Valeria De Braud, Filippo Generali, Daniele Cancers (Basel) Article SIMPLE SUMMARY: The combination of everolimus and exemestane was FDA approved after BOLERO-2 clinical trial results for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC), progressing on a prior therapy with a non-steroideal aromatase inhibitor. However, there are no predictive biomarkers for tumor sensitivity or resistance to everolimus-based treatment. The aim of our retrospective study was to investigate the potential role of FDG-PET SUV (ΔSUV%) as a predictive biomarker for a long-term clinical benefit. We found in a homogenous population of 31 patients two precocious ∆SUV% thresholds capable of identifying HR+ HER2-mBC patients achieving long-term benefit or long-term survival (36 month-OS) during everolimus-exemestane therapy. Based on these results, ∆SUV, as PET-based biomarker, provides additional information on which patients are most likely to benefit from everolimus with exemestane-based therapy over a long-term period. FDG-PET is a useful and minimally invasive tool that could be used for making a decision on personal treatment enhancing benefit while reducing collateral effects. ABSTRACT: Background: The mTORC1 inhibitor everolimus has been approved in combination with the aromatase inhibitor exemestane for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (HR+ mBC) progressing on prior therapy with a non-steroidal aromatase inhibitor. To date, no predictive biomarkers of tumor sensitivity/resistance for everolimus-based treatments have been identified. We hypothesized that precocious changes in the Standardized Uptake Volume (∆SUV%), as assessed by (18)F-Fluorodeoxyglucosepositron-emission tomography ((18)F-FDG PET/CT), may be a marker of everolimus efficacy. Methods: This was a retrospective study including 31 HR+ HER2- patients treated with everolimus and exemestane in two Italian centers between 2013 and 2018. The objective of the study was to investigate ∆SUV% as a predictive marker of everolimus antitumor efficacy. (18)F-FDG PET/CT scans were performed at baseline and after three months of treatment. Patients were defined as long responders (LRs) if disease progression occurred at least 10 months after treatment initiation and long survivors (LSs) if death occurred later than 36 months after starting therapy. ROC analysis was used to determine the optimal cut-off values of ∆SUV% to distinguish LRs from non-LRs and LSs from non-LSs. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan–Meier method. Results: The SUVmax values decreased significantly from baseline to 3 months after therapy (p = 0.003). Dynamic changes of SUVmax (Delta SUV) had a higher accuracy in discriminating long-responders from non-long-responders (AUC = 0.67, Delta SUV cut-off = 28.8%) respects to its ability to identify long survivors from no-long survivors (AUC = 0.60, Delta SUV cut-off = 53.8%). Patients were divided into groups according to the Delta SUV cut-offs and survival outcomes were evaluated: patients with a decrease of ∆SUV% ≥ 28.8% had significantly better PFS (10 months-PFS: 63.2%, 95% CI: 37.9–80.4% and 16.7%, 95% CI: 2.7–41.3% respectively, p = 0.005). As regard as OS, patients with ∆SUV% ≥ 53.8% had longer OS when compared to patients with ∆SUV% < 53.8% (36 month-OS: 82.5% vs. 45.9% vs. p = 0.048). Conclusion: We found two precocious ∆SUV% thresholds capable of identifying HR+ HER2-mBC patients, which would achieve long-term benefit or long-term survival during everolimus-exemestane therapy. These results warrant further validation in prospective studies and should be integrated with molecular biomarkers related to tumor metabolism and mTORC1 signaling. MDPI 2020-11-10 /pmc/articles/PMC7697290/ /pubmed/33182575 http://dx.doi.org/10.3390/cancers12113314 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sirico, Marianna
Bernocchi, Ottavia
Sobhani, Navid
Giudici, Fabiola
Corona, Silvia P.
Vernieri, Claudio
Nichetti, Federico
Cappelletti, Maria Rosa
Milani, Manuela
Strina, Carla
Cervoni, Valeria
Barbieri, Giuseppina
Ziglioli, Nicoletta
Dester, Martina
Bianchi, Giulia Valeria
De Braud, Filippo
Generali, Daniele
Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title_full Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title_fullStr Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title_full_unstemmed Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title_short Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
title_sort early changes of the standardized uptake values (suv(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697290/
https://www.ncbi.nlm.nih.gov/pubmed/33182575
http://dx.doi.org/10.3390/cancers12113314
work_keys_str_mv AT siricomarianna earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT bernocchiottavia earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT sobhaninavid earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT giudicifabiola earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT coronasilviap earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT verniericlaudio earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT nichettifederico earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT cappellettimariarosa earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT milanimanuela earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT strinacarla earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT cervonivaleria earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT barbierigiuseppina earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT zigliolinicoletta earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT destermartina earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT bianchigiuliavaleria earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT debraudfilippo earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer
AT generalidaniele earlychangesofthestandardizeduptakevaluessuvmaxpredicttheefficacyofeverolimusexemestaneinpatientswithhormonereceptorpositivemetastaticbreastcancer